SynCore Biotechnology EBITDA vs. Current Ratio
| 4192 Stock | TWD 35.40 0.20 0.56% |
For SynCore Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of SynCore Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well SynCore Biotechnology Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between SynCore Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of SynCore Biotechnology Co over time as well as its relative position and ranking within its peers.
SynCore |
SynCore Biotechnology Current Ratio vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining SynCore Biotechnology's current stock value. Our valuation model uses many indicators to compare SynCore Biotechnology value to that of its competitors to determine the firm's financial worth. SynCore Biotechnology Co is number one stock in ebitda category among its peers. It also is number one stock in current ratio category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SynCore Biotechnology's earnings, one of the primary drivers of an investment's value.SynCore Current Ratio vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
SynCore Biotechnology |
| = | (404.13 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
SynCore Biotechnology |
| = | 5.04 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
SynCore Current Ratio Comparison
SynCore Biotechnology is currently under evaluation in current ratio category among its peers.
SynCore Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in SynCore Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, SynCore Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of SynCore Biotechnology's change in net profit over the period of time. It can combine multiple indicators of SynCore Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally. The company was founded in 2008 and is headquartered in Yilan, Taiwan. SYNCORE BIOTECHNOL operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 81 people.
SynCore Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on SynCore Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of SynCore Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the SynCore Biotechnology's important profitability drivers and their relationship over time.
Use SynCore Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SynCore Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SynCore Biotechnology will appreciate offsetting losses from the drop in the long position's value.SynCore Biotechnology Pair Trading
SynCore Biotechnology Co Pair Trading Analysis
The ability to find closely correlated positions to SynCore Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SynCore Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SynCore Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SynCore Biotechnology Co to buy it.
The correlation of SynCore Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SynCore Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SynCore Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SynCore Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your SynCore Biotechnology position
In addition to having SynCore Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for SynCore Stock Analysis
When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.